Prognostic utility of biochemical markers of cardiovascular risk: Impact of biological variability

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 9, 2013, Pages 1875-1882

  Alexander, Kristine S ^a   Kazmierczak, Steven C ^a,b   Snyder, Caryn K ^b   Oberdorf, Jon A ^c   Farrell, David H ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b DiabetOmics LLC   (United States)

^c Gamma Therapeutics Inc   (United States)

Author keywords

Biomarker; Cardiovascular disease; Inflammation; Risk factor; Variation

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; GAMMA FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LIMIT OF DETECTION; MALE; MEASUREMENT ACCURACY; NORMAL HUMAN; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; VALIDITY; VARIANCE;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84888121074     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0750     Document Type: Article

References (28)

1. Block G, Dietrich M, Norkus E, Jensen C, Benowitz NL, Morrow JD, et al. Intraindividual variability of plasma antioxidants, markers of oxidative stress, C-reactive protein, cotinine, and other biomarkers. Epidemiology 2006;17: 404-12. (Pubitemid 44305513)
2. Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367: 1310-20.
3. Lovely RS, Falls LA, Al-Mondhiry HA, Chambers CE, Sexton GJ, Ni H, et al. Association of γA/γ́ fibrinogen levels and coronary artery disease. Thromb Haemost 2002;88: 26-31. (Pubitemid 34752262)
4. Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegård A, Farrell DH, et al. Elevated plasma fibrinogen γ́ concentration is associated with myocardial infarction: effects of variation in fibrinogen genes and environmental factors. J Thromb Haemost 2007;5: 766-73. (Pubitemid 46563576)
5. Lovely RS, Yang Q, Massaro JM, Wang J, D'Agostino RB Sr, O'Donnell CJ, et al. Assessment of genetic determinants of the association of γ́fibrinogen in relation to cardiovascular disease. Arterioscler Thromb Vasc Biol 2011;31: 2345-52.
6. Cheung EY, de Willige SU, Vos HL, Leebeek FW, Dippel DW, Bertina RM, et al. Fibrinogen γ́in ischemic stroke: a case-control study. Stroke 2008;39: 1033-5. (Pubitemid 351619556)
7. Alesci S, Borggrefe M, Dempfle CE. Effect of freezing method and storage at -20°C and -70°C on prothrombin time, aPTT and plasma fibrinogen levels. Thromb Res 2009;124: 121-6.
8. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen plasma. Blood Coagul Fibrinolysis 2001;12: 229-36. (Pubitemid 32575155)
9. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, Kuller LH, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999;149: 261-7. (Pubitemid 29053167)
10. De Bacquer D, De Backer G, Braeckman L, Baele G. Intra-individual variability of fibrinogen levels. J Clin Epidemiol 1997;50: 393-9. (Pubitemid 27223268)
11. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107: 499-511. (Pubitemid 36158056)
12. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010;121:948-54;
13. erratum in: Circulation 2010;121:e259.
14. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al.; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16;
15. erratum in: Circulation. 2009;119:e606.
16. Clark GH, Fraser CG. Biological variation of acute phase proteins. Ann Clin Biochem 1993;30: 373-6. (Pubitemid 23222952)
17. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47: 444-50. (Pubitemid 32222458)
18. McCormack JP, Allan GM. Measuring hsCRP-an important part of a comprehensive risk profile or a clinically redundant practice? PLoS Med 2010;7:e1000196.
19. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med 2006;166: 1368-73. (Pubitemid 44036348)
20. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, McCormack V, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009;38: 217-31.
21. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355: 2631-9. (Pubitemid 44969122)
22. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012;156: 438-44.
23. Campbell B, Badrick T, Flatman R, Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 2002;39: 85-8. (Pubitemid 34214362)
24. Alexander KS, Madden TE, Farrell DH. Association between γ́fibrinogen levels and inflammation. Thromb Haemost 2011;105: 605-9.
25. Cheung EY, Vos HL, Kruip MJ, den Hertog HM, Jukema JW, de Maat MP. Elevated fibrinogen γ́ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome. Blood 2009;114:4603-4; author reply 4604-5.
26. Rein CM, Anderson NW, Farrell DH. Differential regulation of fibrinogen γ chain splice isoforms by interleukin-6. 2013;131: 89-93.
27. Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, et al.; Fibrinogen Concentrate Study Group. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009;7: 2064-9.
28. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91: 1351-7. (Pubitemid 23127332)